phrykt

Lb Pharmaceuticals Inc (LBRX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of LBRX were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling LB Pharmaceuticals

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LBRX

116 funds and institutions reported LBRX shares worth $1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Deep Track Capital, LP with 11.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Deep Track Capital, LP11.7%
BlackRock, Inc.9.5%
Ra Capital Management, L.P.7.7%
Nantahala Capital Management, LLC7.3%
Trails Edge Capital Partners, LP5.3%
Commodore Capital LP5.2%
JPMorgan Chase & Co5.2%
TCG Crossover Management, LLC5.0%
Caligan Partners LP5.0%
Spruce Street Capital LP4.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Deep Track Capital, LP3.35M11.69%$109MNo change
BlackRock, Inc.2.73M9.54%$88.7M+11%
Ra Capital Management, L.P.2.21M7.70%$71.7MNo change
Nantahala Capital Management, LLC2.11M7.34%$68.3M+100%
Trails Edge Capital Partners, LP1.52M5.31%$49.4M+15%
Commodore Capital LP1.50M5.23%$48.7MNo change
JPMorgan Chase & Co1.50M5.22%$48.9MNew
TCG Crossover Management, LLC1.45M5.05%$47M-21%
Caligan Partners LP1.44M5.02%$46.7MNo change
Spruce Street Capital LP1.38M4.80%$44.7MNo change
Vanguard Capital Management LLC971,1653.39%$31.5M+9%
Balyasny Asset Management L.P.921,4713.21%$29.9M-0%
Alyeska Investment Group, L.P.863,9473.01%$28MNo change
Vivo Capital, LLC800,0002.79%$26MNo change
Nan Fung Group Holdings Ltd630,6572.20%$20.5MNo change
Geode Capital Management, LLC612,7932.14%$19.9M+18%
State Street Corp602,0282.10%$19.5M+19%
Logos Global Management LP585,0002.04%$19M-36%
Goldman Sachs Group Inc576,4562.01%$18.7M+58%
Jennison Associates LLC540,9021.89%$17.6M+0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No LBRX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LBRX short interest

High short interest. 19.2% of LBRX shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 54%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.20M LBRX shares were sold short, 19.2% of the shares outstanding, up 11.4% from the report before. At the average daily volume of 344,721 shares, buying them all back would take about 18.0 trading days (days to cover).

Shares short, % of all shares

19.2%May 15Oct 3020.0%

Days to cover

18.0May 15Oct 3034.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.20M19.22%+11%344,72118.0
Oct 15, 20265.56M17.25%-7%458,48812.1
Sep 30, 20266.01M18.63%+7%414,30114.5
Sep 15, 20265.62M17.41%+6%261,86321.4
Aug 31, 20265.28M16.36%+2%265,34519.9
Aug 14, 20265.16M15.98%+9%416,37312.4
Jul 31, 20264.75M16.55%+11%370,84712.8
Jul 15, 20264.26M14.86%-6%242,21117.6
Jun 30, 20264.55M15.87%+6%465,3319.8
Jun 15, 20264.30M15.00%+7%173,85424.8
May 29, 20264.02M14.00%-0%184,10721.8
May 15, 20264.02M14.01%+6%128,87331.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

LB Pharmaceuticals company events

LB Pharmaceuticals filed 13 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 15, 2026LeadershipLB Pharmaceuticals Inc announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026. Filing
  3. Sep 3, 2026LeadershipLB Pharmaceuticals Inc announced that Joseph M. Miller has been appointed to serve as the Company’s Chief Financial Officer, effective as of September 2, 2026. Filing
  4. Aug 11, 2026ResultsReleased financial results. Filing
  5. Jul 29, 2026AgreementLB Pharmaceuticals Inc entered into a Securities Purchase Agreement with certain investors pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of (i) 3,577,560 shares of the Company’s common stock, par value $0.0001 per share and (ii)… Filing
  6. Jul 22, 2026AnnouncementLB Pharmaceuticals Inc issued a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. Filing
  7. Jun 10, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
  8. Jun 9, 2026VoteReported shareholder vote results. Filing
  9. May 12, 2026ResultsReleased financial results. Filing
  10. Mar 26, 2026ResultsReleased financial results. Filing
  11. Mar 16, 2026LeadershipZachary Prensky notified the Board of Directors of LB Pharmaceuticals Inc of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders. Filing
  12. Mar 10, 2026LeadershipThe Board of Directors of LB Pharmaceuticals Inc appointed Robert A. Lenz, to the Board, effectively immediately. Filing
  13. Feb 5, 2026AgreementLB Pharmaceuticals Inc entered into a Securities Purchase Agreement with certain investors pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares of the Company’s common stock, par value $0.0001 per share and (ii)… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

LB Pharmaceuticals financials

Famous investors that hold LBRX

4 of the 50 well-known investors we track reported holding LBRX in their latest 13F filing. The largest position is Ken Griffin's, worth $8.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026225,240$8.6M0.0%+4%
Israel Englander · Millennium ManagementQ3 2026172,840$6.6M0.0%-33%
Steve Cohen · Point72 Asset ManagementQ3 202691,309$3.5M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202616,129$619K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named LBRX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Commodore Capital LP13G/A5.8%
Nov 16, 2026TCG Crossover GP II, LLC13G/A2.4%
Nov 16, 2026Trails Edge Capital Partners, LP13G/A3.6%
Nov 16, 2026Commodore Capital LP13G/A5.8%
Nov 16, 2026TCG Crossover GP II, LLC13G/A2.4%
Nov 16, 2026Trails Edge Capital Partners, LP13G/A3.6%
Oct 13, 2026JPMORGAN CHASE & CO.13G/A4.3%
Oct 13, 2026JPMORGAN CHASE & CO.13G/A4.3%

Questions about Lb Pharmaceuticals Inc (LBRX) stock

Who owns the most LBRX stock?

The largest reported owner of Lb Pharmaceuticals Inc (LBRX) is Deep Track Capital, LP, with 11.7% of the company. In total, 116 funds and institutions reported holding LBRX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are LBRX insiders buying or selling?

No LBRX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in LBRX?

As of Oct 30, 2026, 6.20M LBRX shares were sold short, 19.2% of the shares outstanding, up 11.4% from the report before. At the average daily volume of 344,721 shares, buying them all back would take about 18.0 trading days (days to cover). See the history.

Which famous investors hold LBRX?

4 of the 50 well-known investors we track reported LBRX in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $8.6M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.